ReviewDiscover oncology2025
Research progress on the role of AGC kinase family in bladder cancer.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- RPL17 regulates the progression of breast cancer accompanied by MAPK signaling activation.Medical oncology (Northwood, London, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Bladder cancer is a common malignant tumor worldwide, with rising incidence and mortality rates. In recent years, the role of the AGC kinase family (including PKA, PKC, PKG, etc.) in the initiation, progression, and metastasis of bladder cancer has attracted widespread attention. AGC kinases regulate various cellular processes such as proliferation, migration, metabolism, and apoptosis through phosphorylation of specific substrates. Aberrant activation or expression of these kinases is closely associated with the malignant progression of bladder cancer. This review summarizes the current research on the AGC kinase family in bladder cancer, focusing on the roles of PKA, PKC, and PKG in bladder cancer cell biology, and discusses key signaling pathways related to these kinases, such as the PI3K/Akt and MAPK/ERK pathways. Furthermore, the potential of AGC kinases as therapeutic targets has been extensively explored, with preclinical studies showing promising results for targeted inhibitors and combination therapies. Finally, we discuss future research directions, including molecular mechanisms of AGC kinases, the development of targeted therapies, and clinical trial design, aiming to provide a theoretical basis and strategy for bladder cancer treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.